• Featured Product
  • KD/KO Validated

RERG Polyklonaler Antikörper

RERG Polyklonal Antikörper für WB, ELISA

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

human, Maus

Anwendung

WB, IHC, IF, ELISA

Konjugation

Unkonjugiert

Kat-Nr. : 10687-1-AP

Synonyme

RERC, RERG



Geprüfte Anwendungen

Erfolgreiche Detektion in WBNIH/3T3-Zellen, MCF-7-Zellen

Empfohlene Verdünnung

AnwendungVerdünnung
Western Blot (WB)WB : 1:1000-1:6000
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, check data in validation data gallery

Produktinformation

10687-1-AP bindet in WB, IHC, IF, ELISA RERG und zeigt Reaktivität mit human, Maus

Getestete Reaktivität human, Maus
In Publikationen genannte Reaktivitäthuman
Wirt / Isotyp Kaninchen / IgG
Klonalität Polyklonal
Typ Antikörper
Immunogen RERG fusion protein Ag1041
Vollständiger Name RAS-like, estrogen-regulated, growth inhibitor
Berechnetes Molekulargewicht 23 kDa
Beobachtetes Molekulargewicht 23-26 kDa
GenBank-ZugangsnummerBC007997
Gene symbol RERG
Gene ID (NCBI) 85004
Konjugation Unkonjugiert
Form Liquid
Reinigungsmethode Antigen-Affinitätsreinigung
Lagerungspuffer PBS mit 0.02% Natriumazid und 50% Glycerin pH 7.3.
LagerungsbedingungenBei -20°C lagern. Nach dem Versand ein Jahr lang stabil Aliquotieren ist bei -20oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

RERG (Ras-related and estrogen-regulated growth inhibitor), a gene that encodes a small GTP binding and hydrolyzing protein (GTPase) of the Ras superfamily, is a novel gene that was first reported in breast cancer. RERG gene expression is stimulated by the estrogen receptor alpha (ERalpha), and RERG gene expression is absent in ER-negative breast cancer. RERG can bind and hydrolyze GTP as a GTP/GDP molecular switch, and RERG has been shown to possess growth inhibitory activity in breast cancer cells.

Protokolle

Produktspezifische Protokolle
WB protocol for RERG antibody 10687-1-APProtokoll herunterladen
Standard-Protokolle
Klicken Sie hier, um unsere Standardprotokolle anzuzeigen

Publikationen

SpeciesApplicationTitle
humanWB,IF

Front Oncol

The NFAT3/RERG Complex in Luminal Breast Cancers Is Required to Inhibit Cell Invasion and May Be Correlated With an Absence of Axillary Lymph Nodes Colonization.

Authors - Lucie Coillard
  • KD Validated
humanIHC

Breast Cancer Res Treat

RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.

Authors - Habashy Hany Onsy HO

Oncol Rep

ERK5‑regulated RERG expression promotes cancer progression in prostatic carcinoma.

Authors - Ying Xiong
humanWB,IHC

Oncotarget

MicroRNA-382-5p aggravates breast cancer progression by regulating the RERG/Ras/ERK signaling axis.

Authors - Jar-Yi Ho
humanIHC

Front Med (Lausanne)

Missing link between tissue specific expressing pattern of ERβ and the clinical manifestations in LGBLEL

Authors - Xujuan Zhang